Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

被引：25
|
作者：
Pemmaraju, Naveen [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, POB 301402, Houston, TX 77230 USA
来源：
CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2017年 / 12卷 / 06期
关键词：
BPDCN; IL3R; CD123; Targeted therapy; Bromodomain; BCL2; NFkB; WORLD-HEALTH-ORGANIZATION; T-CELLS; MYELOID NEOPLASMS; RECEPTOR-ALPHA; LEUKEMIA; TRANSPLANTATION; CLASSIFICATION; INHIBITION; REVISION;
D O I：
10.1007/s11899-017-0425-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：510 / 512
页数：3
相关论文
共 50 条
  • [31] Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCNIncreasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community
    Pemmaraju, Naveen
    Utengen, Audun
    Gupta, Vikas
    Thompson, Michael A.
    Lane, Andrew A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (06) : 581 - 587
  • [32] Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Pemmaraju, Naveen
    Gupta, Vikas
    Thompson, Michael A.
    Lane, Andrew A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (06) : 462 - 467
  • [33] Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Naveen Pemmaraju
    Vikas Gupta
    Michael A. Thompson
    Andrew A. Lane
    Current Hematologic Malignancy Reports, 2016, 11 : 462 - 467
  • [34] CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123
    Hu, Xiaoyi
    Ediriwickrema, Asiri
    Saleem, Atif
    Tan, Brent
    Pemmaraju, Naveen
    Mannis, Gabriel N.
    LEUKEMIA RESEARCH, 2024, 139
  • [35] Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123Targeted Therapy
    Pemmaraju, Naveen
    Cuglievan, Branko
    Lasky, Joseph
    Kheradpour, Albert
    Hijiya, Nobuko
    Stein, Anthony S.
    Meshinchi, Soheil
    Mullen, Craig
    Angelucci, Emanuele
    Vinti, Luciana
    Mughal, Tariq I.
    Pawlowska, Anna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S244 - S245
  • [36] Novel treatment of blastic plasmacytoid dendritic cell neoplasm: A case report
    Grushchak, Solomiya
    Joy, Cossette
    Gray, Arielle
    Opel, Dan
    Speiser, Jodi
    Reserva, Jeave
    Tung, Rebecca
    Smith, Scott E.
    MEDICINE, 2017, 96 (51)
  • [37] Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm
    Philippe, Laure
    Ceroi, Adam
    Bole-Richard, Elodie
    Jenvrin, Alizee
    Biichle, Sabeha
    Perrin, Sophie
    Limat, Samuel
    Bonnefoy, Francis
    Deconinck, Eric
    Saas, Philippe
    Garnache-Ottou, Francine
    Angelot-Delettre, Fanny
    HAEMATOLOGICA, 2017, 102 (11) : 1861 - 1868
  • [38] Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm
    Economides, Minas P.
    McCue, Deborah
    Lane, Andrew A.
    Pemmaraju, Naveen
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (10) : 941 - 946
  • [39] Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations
    Pemmaraju, Naveen
    Madanat, Yazan F.
    Rizzieri, David
    Fazal, Salman
    Rampal, Raajit
    Mannis, Gabriel
    Wang, Eunice S.
    Foran, James
    Lane, Andrew A.
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 548 - 559
  • [40] Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches
    Cheng, Wei
    Yu, Tian-tian
    Tang, Ai-ping
    He Young, Ken
    Yu, Li
    CURRENT MEDICAL SCIENCE, 2021, 41 (03) : 405 - 419
12345